H01 Navigating Cancer Clinical Trials: Essential Knowledge 2026Info Location Contact More Info Event Information
DescriptionThis course offers a practical introduction to the key clinical and scientific concepts that underpin the design and conduct of cancer clinical trials. Participants will explore the biology of cancer, how tumours grow and spread, and how these factors influence treatment decisions and trial methodology. The programme covers the full pathway from diagnosis and staging through to treatment delivery, assessment, analysis, and reporting, highlighting how each stage contributes to high‑quality trial outcomes.
Attendees will gain insight into commonly reported patient and tumour characteristics, including how these factors affect eligibility, stratification, and interpretation of trial findings. The course also examines the main cancer treatment modalities and the practical considerations involved in documenting treatment administration, monitoring adherence, and capturing protocol compliance.
Location: Maple House 149 Tottenham Ct Rd, London W1T 7NF Venue details: further details to follow
Event Location
ContactFor all queries relating to this Course please contact the following :-
PLEASE ONLY CONTACT THE ONLINE STORE DIRECTLY IF YOU ARE EXPERIENCING PROBLEMS WITH YOUR DEBIT/CREDIT CARD PAYMENT, FOR ALL OTHER QUERIES RELATING TO THIS COURSE, INCLUDING CANCELLATIONS THESE SHOULD BE DIRECTED TO THE CONTACT DETAILS ABOVE. More InformationA substantial focus is placed on understanding adverse events associated with cancer therapies, with guidance on accurate assessment and reporting. The course also addresses response evaluation in both solid and haematological malignancies, explaining the principles behind response‑based endpoints and the methodologies used to measure them. Participants will further develop their understanding of survival and other time‑to‑event outcomes that are central to clinical trial analysis.
Finally, the course explores the unique challenges presented by emerging therapies, including targeted agents and biomarker‑driven approaches, and how these innovations shape trial design and data interpretation. The programme provides a valuable opportunity for professionals from diverse backgrounds to share experiences, deepen their knowledge, and build connections across the cancer trials community.
| |||||||||||||||
London's global university
